# Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

> **NCT00246610** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 16 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** Nelfinavir mesylate, 625 mg

## Key facts

- **NCT ID:** NCT00246610
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2011-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00246610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00246610, "Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00246610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*